Skip to content
  • info@BioLifeSolutions.com
  • 1.866.424.6543
  • Toggle search form
  • Toggle shopping cart 0

    Cart

  • Products
    • CryoStor®
      • CryoStor CS10
      • CryoStor CS5
      • CryoStor CS2
      • CryoStor CSB
    • HypoThermosol®
      • HypoThermosol®
      • HypoThermosol for Hair
    • ThawSTAR® Products
      • ThawSTAR CB
      • ThawSTAR CFT2
      • AT6
      • CFT1.5
      • CFT2 Confirmation Vials
      • Warranty and PM
      • IOP Qualification Packet
      • BioT ULT Transporter
      • BioT LN2 Transporter
      • BioT ULT Mobile Workstation
    • BloodStor®
      • BloodStor 100
      • BloodStor 55-5
      • BloodStor 27
    • Cell Thawing Media®
      • 10% Dextran 40 (IN 0.9% NaCl)
      • 10% Dextran 40 (IN 5% Dextrose)
    • All Products
  • Resources
    • Certificate of Analysis
    • Blog
    • Events
    • BioPreservation Today
    • White Papers
    • Press Releases
  • Evidence
    • Resource Links
  • Company
    • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Quality Management System
    • Distributors
    • Current Job Openings
  • Investors
    • Investors Home
    • Governance
    • Press Releases
    • Financials
    • Stock Information
    • Management Team
    • Investor Contact
  • Contact
    • General Inquiries
    • ThawSTAR Inquiries
    • Master File Request
    • SDS Request Form
    • Sample Request
    • evo Support Request
  • Ask the Scientists
  • ORDER
Close navigation
  • Primary Menu
logo

BioLife Solutions

Biopreservation Tools For Cells, Tissues, and Organs

Close search

Search

Search for:
Home/Cryopreservations/Intent to treat...

Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults

Gardner R, Finney O, Annesley C, Brakke H, Summers C, Leger K, Bleakley M, Brown C, Mgebroff S, Spratt K, Hoglund V, Lindgren C, Oron A, Li D, Riddell S, Park J, Jensen M. Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults. Blood 2017 :blood-2017-02-769208. doi: https://doi.org/10.1182/blood-2017-02-769208

Post navigation

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
In Vivo Maturation of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Neonatal and Adult Rat Hearts
Search for:

Blog Archives

Signup Area

    Sign Up for Email Updates

    Biolife Logo

    • Products
    • Company
    • Evidence
    • Investors
    • Blog
    • Ask the Scientists
    • Press Releases
    • Contact
    © 2019 BioLifeSolutions Inc.  All Rights Reserved    |    Terms & Conditions    |    Privacy
    • twitter
    • linkedin
    • facebook